COX-2 inhibition with Celecoxib does not improve breast cancer outcomes

COX-2 inhibition with celecoxib does not prolong disease free survival or overall survival among patients who undergo complete resection of primary breast cancer, with or without adjuvant or neoadjuvant chemotherapy and/or radiotherapy, according to findings presented at the 2017 San Antonio Breast Cancer Symposium.
Cancer Therapy Advisor